Osiris Therapeutics to Present at 27th Annual J.P. Morgan Healthcare Conference (12/22/08)

Osiris Receives Approval for Prochymal Expanded Access Program in Canada (12/05/08)

Osiris Completes Enrollment in First Worldwide Phase III Stem Cell Trial (12/04/08)

Osiris Therapeutics to Present at 20th Annual Piper Jaffray Health Care Conference (11/26/08)

Osiris Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference (11/06/08)

Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products (11/04/08)

Osiris Therapeutics Reports Third Quarter 2008 Financial Results (11/04/08)

Osiris Announces Third Quarter 2008 Financial Results Conference Call (10/31/08)

Osiris Therapeutics to Present at the 7th Annual BIO Investor Forum (10/27/08)

Osiris Therapeutics to Present at the JMP Securities Healthcare Focus Conference (10/02/08)

Osiris Completes Enrollment of Stem Cell Trial to Treat Pulmonary Disease (09/23/08)

Osiris Therapeutics to Present at the 2008 UBS Global Life Sciences Conference (09/18/08)

Osiris Therapeutics to Present at Thomas Weisel Partners Healthcare Conference (08/28/08)

Osiris Therapeutics Reports Second Quarter 2008 Financial Results (08/07/08)

Osiris Announces Second Quarter 2008 Financial Results Conference Call (08/04/08)

Osiris Therapeutics Appoints Chief Financial Officer (07/28/08)

Osiris Therapeutics Closes Osteocel Transaction Worth up to $137 Million (07/24/08)

Osiris Therapeutics Announces $2 Million Milestone Payment for Clinical Progress of a Stem Cell Therapy for Type 1 Diabetes (06/25/08)

Osiris Therapeutics to Present at the Piper Jaffray Europe Conference (06/18/08)

Osiris Therapeutics to Present at the Jefferies Second Annual Healthcare Conference (06/18/08)

Osiris Therapeutics to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference (06/10/08)

Osiris Therapeutics to Present at the Canaccord Adams Diabetes and Obesity Conference (06/03/08)

Osiris Therapeutics Initiates Phase II Clinical Trial Evaluating Prochymal™ for Chronic Obstructive Pulmonary Disease (05/21/08)

Osiris Therapeutics Reports First Quarter 2008 Financial Results (05/09/08)

Osiris and NuVasive Enter into Definitive Agreement for Osteocel® (05/08/08)

Osiris Receives Approval for Use of Prochymal™ Under FDA Expanded Access Treatment Program (05/07/08)

Osiris Announces First Quarter 2008 Financial Results Conference Call (05/06/08)

Osiris Therapeutics to Present at the Lehman Brothers Healthcare Conference (03/17/08)

Osiris Therapeutics Reports Record Fourth Quarter and Full Year 2007 Financial Results (02/28/08)

Osiris Therapeutics Strengthens Management Team (02/27/08)

Prochymal™ Demonstrates Lasting Benefit in Heart Attack Patients; Osiris Receives FDA Clearance to Start Phase II Trial (02/26/08)

Osiris Announces Fourth Quarter and Full Year 2007 Financial Results Conference Call (02/25/08)

Osiris Therapeutics to Present at the 10th Annual BIO CEO and Investor Conference (02/06/08)

Osiris Therapeutics to Present at the Leerink Swann Novel Biologics Therapeutics Roundtable Conference (01/18/08)

Osiris Therapeutics to Receive Milestone Payment from JCR Pharmaceuticals (01/07/08)

Osiris Therapeutics Regains Worldwide Rights to Cardiovascular Indications for Prochymal™ (01/07/08)

Osiris Therapeutics Awarded Department of Defense Contract for Prochymal Fully Valued at $224.7 Million (01/03/08)

Osiris Therapeutics Completes $12 Million Private Placement and Eliminates $19 Million of Debt Through Common Stock Conversion (12/20/07)

Osiris Therapeutics Reports Positive Results for Prochymal™ as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease (12/10/07)

Use of Mesenchymal Stem Cells (Prochymal )to Treat Pediatric Patients with Severe (Grade III-IV) acute Graft Versus Host Disease Refractory to Steroid and Other Agents (12/10/07)

Osiris Therapeutics Receives FDA Fast Track Status for Prochymal™ as First-Line Treatment for Acute GvHD (12/07/07)

Osiris Therapeutics Announces Positive One Year Data from Chondrogen Trial for Knee Repair (11/27/07)

Osiris Therapeutics to Present at the 19th Annual Piper Jaffray Health Care Conference (11/26/07)

Osiris Therapeutics to Present at 20th Annual Piper Jaffray Health Care Conference (11/26/07)

Osiris Therapeutics Announces Management Change (11/23/07)

Osiris Therapeutics Reports Third Quarter 2007 Financial Results (11/12/07)

Osiris Therapeutics to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference (11/08/07)

Osiris Announces Third Quarter 2007 Financial Results Conference Call (11/08/07)

Osiris Therapeutics Initiates Phase II Clinical Trial Evaluating Prochymal™ for Type 1 Diabetes (10/25/07)

Osiris Therapeutics Receives FDA Clearance to Initiate Phase III Pivotal Trial for Prochymal™ as a First Line Treatment for Acute Graft vs. Host Disease (10/17/07)

Osiris Therapeutics Secures $30 Million Financing Commitment from Chairman and Largest Shareholder (10/09/07)

Major Shareholders of Osiris Therapeutics Elect to Extend Lock-up Agreement (09/20/07)

Osiris Therapeutics to Present at the ThinkEquity Partners’ Fifth Annual Growth Conference (09/14/07)

Osiris Therapeutics to Present at the Thomas Weisel Partners Healthcare Conference 2007 (08/31/07)

Osiris Therapeutics Appoints Nuclear and Radiological Countermeasure Advisory Board (08/30/07)

Osiris Therapeutics Reports Second Quarter 2007 Financial Results (08/09/07)

Osiris Announces Second Quarter 2007 Financial Results Conference Call (08/07/07)

Osiris and Genzyme Partner to Develop Medical Countermeasures for Nuclear and Radiological Threats (07/26/07)

Osiris Therapeutics to Present at Jefferies Healthcare Conference (06/22/07)

Osiris Therapeutics Announces $20 million Private Placement (06/06/07)

Osiris Therapeutics Reports First Quarter 2007 Financial Results (05/14/07)

Osiris Therapeutics Added to NASDAQ Biotechnology Index (05/14/07)

Osiris Announces First Quarter 2007 Financial Results Conference Call (05/09/07)

Osiris Named Biotechnology Company of the Year (05/03/07)

Osiris Adult Stem Cells Help Heart Attack Patients in Study (03/25/07)

Osiris Therapeutics Announces Positive Results in Groundbreaking Stem Cell Trial to Treat Heart Disease (03/25/07)

Osiris Therapeutics Announces that Results of Stem Cell Trial to Treat Heart Disease will be Presented at American College of Cardiology Conference (03/23/07)

Osiris Therapeutics Reports Fourth Quarter & Full Year 2006 Financial Results (02/19/07)

Osiris to Report Fourth Quarter & Full Year 2006 Financial Results (02/15/07)

Osiris Announces Top-Line Interim Results for Stem Cell Trial for Knee Repair (02/12/07)

Osiris Therapeutics Receives European Orphan Drug Designation for PROCHYMAL™ (01/15/07)

Osiris Therapeutics Receives FDA Fast Track Status for its Crohn's Disease Stem Cell Therapy and Clearance to Start Phase III Clinical Trial (01/08/07)

Phase II Trial of Prochymal™ (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) and Corticosteroids as Primary Treatment for Acute Graft-Vs-Host Disease (aGVHD). (12/11/06)

Osiris Therapeutics Provides Update on Phase II Trial Evaluating PROCHYMAL™ for the Treatment of Acute Graft vs. Host Disease (12/09/06)

Osiris Therapeutics to Present at Lazard Life Sciences Conference (11/22/06)

Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL™ for the Treatment of Acute Graft vs. Host Disease (11/09/06)

Osiris Therapeutics Successfully Completes Private Placement with Friedli Corporate Finance (11/08/06)

Osiris Announces Third Quarter 2006 Financial Results Conference Call (10/31/06)

Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL™ in Treatment-Resistant Crohn’s Disease (10/19/06)

Osiris is Granted European Manufacturing Certification for PROCHYMAL(TM) (10/17/06)

Osiris Therapeutics Receives Approval from Health Canada to Conduct Phase III Clinical Trial for Lead Stem Cell Drug (10/11/06)

Osiris Therapeutics to Present at BIO Investor Forum (10/10/06)

Osiris Therapeutics Named to Russell Index (09/18/06)

Osiris Therapeutics to Present at UBS Global Life Sciences Conference (09/15/06)

Osiris Announces Second Quarter 2006 Financial Results Conference Call (09/08/06)

Osiris Announces Expansion of Board of Directors and Key Additions to its Senior Management Team (08/14/06)

Osiris Announces Pricing of Its Initial Public Offering (08/04/06)

Osiris Updates Information on Initial Public Offering (07/17/06)

Osiris Completes Enrollment in Stem Cell Trial for Knee Repair (04/25/06)

Osiris Completes Enrollment in Stem Cell Trial to Treat Cardiac Disease (04/05/06)

Osiris Stem Cell Funding Totals $70 Million for 2005 (12/21/05)

Osiris Receives Orphan Drug Status from FDA for Lead Stem Cell Drug (12/20/05)

Osiris Cleared by FDA to Begin Phase II Stem Cell Trial for the Treatment of Crohn’s Disease (12/08/05)

Osiris Reaches Safety Milestone in Stem Cell Clinical Trial for Cardiac Patients (11/14/05)

New Stem Cell Drug Gives baby Second Chance (10/14/05)

Stem Cell Drug Saves Baby From Blood Disorder (10/14/05)

New stem cell treatment being evaluated for critically ill bone marrow transplant patients (10/12/05)

Osiris Launches the Osteocel Product Line (09/22/05)

Osiris and JCR Pharmaceuticals Reach Milestone, Expand License Agreement (08/04/05)

Osiris Cleared by FDA to Begin Stem Cell Trial for Knee Repair (04/01/05)

Osiris Launches the First Trial Using Adult Universal Stem Cells in Cardiac Patients. (03/31/05)

Osiris First to Announce FDA Fast Track Designation for a Stem Cell Product. (01/31/05)

Osiris Therapeutics, Inc. Strengthens Executive Team. (12/17/04)

Stem Cell Therapy Effectively Treats Heart Attacks in Animals (11/09/04)

Researchers Turn To Adult Stem Cells (08/20/04)

Osiris Therapeutics appoints C. Randal Mills President and Chief Executive Officer (07/06/04)

Osiris Therapeutics and JCR Pharmaceuticals Co., Ltd. announce Mesenchymal Stem Cell alliance for Japan (08/27/03)

Boston Scientific and Osiris Therapeutics Announce Stem Cell Alliance: Alliance to develop and commercialize cardiovascular therapies using adult Mesenchymal Stem Cells (03/11/03)